Clinical Trials Logo
  1. Home
  2. Dry Eye Syndromes
  3. NCT05814757
  4. Details
NCT05814757 Clinical Trial

OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Dry Eye Syndromes Clinical Trial

Official title:
A Randomized, Double-masked, Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT05814757
Other study ID # OTX-DED-2022-C01
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date May 11, 2023
Est. completion date May 31, 2024

Study information
Verified date April 2024
Source Ocular Therapeutix, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED

Description:

Randomized, double-masked, study to evaluate the efficacy and safety of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of the symptoms of dry eye disease (DED). The subjects will be followed for approximately two months.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 100
Est. completion date May 31, 2024
Est. primary completion date April 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - VAS eye dryness severity score = 35 and = 90 at screening. - Investigator assessment of bulbar conjunctival hyperemia grade = 2 (CCLRU; 0 - 4 scale). - Unanesthetized Schirmer of > 0 and = 10 mm. - Must not have used Artificial Tears during the Screening period. - IOP in both eyes = 5 mmHg and =21 mmHg. Exclusion Criteria: - Have worn contact lenses in the 4 weeks prior to the screening visit and/or are unwilling to discontinue use of contact lenses throughout the study period. - Have a history of glaucoma or ocular hypertension or have a history of intraocular pressure (IOP) < 5 mmHg or > 24 mmHg.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• OTX-DED
0.3mg dexamethasone ophthalmic insert
• Controlled Insertion
Collagen Punctal Plug 0.2mm (Controlled Insertion)
• Collagen Punctal Plug
Collagen Punctal Plug 0.2mm (Full Insertion)

Locations
Country Name City State
United States Ocular Therapeutix Memphis Tennessee

Sponsors (1)
Lead Sponsor Collaborator
Ocular Therapeutix, Inc.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Severity of Eye Dryness Score (visual analogue scale (VAS)) Visual Analogue Scale (0 mm - no discomfort to 100mm - maximal (the most) discomfort) Change from baseline (CFB) at Day 15
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Not yet recruiting NCT06379685 - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface. Phase 1
Recruiting NCT04701086 - 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis N/A
Active, not recruiting NCT03697876 - Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel Phase 1
Terminated NCT02815293 - Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye Phase 3
Completed NCT02910713 - Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation N/A
Completed NCT04104997 - A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers Phase 1
Recruiting NCT02595606 - 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Phase 4
Completed NCT01711424 - An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease N/A
Completed NCT01202747 - Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction Phase 2/Phase 3
Completed NCT01015209 - Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers Phase 1
Completed NCT00969280 - Acupuncture for Dry Eye Syndrome Phase 3
Completed NCT01496482 - Comparison of Evaporimetry With the Established Methods of Tear Film Measurement N/A
Completed NCT00756678 - Efficacy and Acceptability of Two Lubricant Eye Drops Phase 4
Completed NCT00739713 - Effects of Sea Buckthorn Oil on Dry Eye N/A
Completed NCT00370747 - Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome Phase 2
Completed NCT00349440 - Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Phase 4
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Completed NCT02871440 - A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye Phase 3
Completed NCT05042960 - Computer Screen Properties Study N/A